1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020

Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020

  • August 2016
  • 350 pages
  • ID: 4397185
  • Format: PDF
  • By Kuick Research


Table of Contents

The outline of human vaccines had an incredible impact on global health system which resulted in intense reduction of mortality and morbidity caused by numerous diseases. Vaccines have led to some of the greatest public health achievements ever, including the eradication of naturally occurring smallpox from the globe and the near eradication of polio. This prophylaxis had a long journey through various roads and tunnels to become the humanities’ key achievement. Despite of the fact, that its mechanism of action remained unclear for centuries. New vaccines coined up in nineteenth century and after the expanded studies of infectious diseases and processed microorganism vaccination has become an intensive subject to be studied. By all the new advances towards the discovery and understanding of various diseases, our species was able to find a way to eradicate them.

In recent years peptides have emerged as the considerable vaccine candidate owning to their simple and cost efficient production & development process. Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Given their attractive pharmacological profile and intrinsic properties, peptides represent an excellent starting point for the design of novel therapeutics. Several peptide vaccines are now being designed and are encountering phase I and phase II clinical trials.

Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.

Cancer immunotherapy by peptide vaccines is one of most emerging and significant segment that could help pharmaceutical companies to generate more revenues and help patients to alleviate their medical condition. Peptide vaccine for treatment of metastatic prostate cancer has been introduced in global market. This segment has tendency towards clinical trials as compared to marketed products. Most of the novel products are at different stages of clinical trials which would be introduced in global market in coming years. Biomarkers like Melanoma-Associated Antigen 1 (MAGE-1) for melanoma cancer vaccine and NY-ESO-1 for lung cancer are being developed. Their development requires state-of-art technology due to which they are still not available in market. But confidently these drugs are going to overcome the all hurdles and will become the best suitable candidates in drug market.

A persistent theme in recent peptide based therapeutics is to trigger adaptive antigen specific responses. The next generation drugs will be designed to deliver defined antigenic peptides, target DCs and PRR agonists. Combinations of carrier with TLR agonists provide new advantages of their cytokine production in enhancing immune response.This is already evident that in ongoing clinical trials that the benefits of using such vaccines will be large however safety concerns with diseases like cancer and HIV are still under critical observations. With the growing knowledge of immunological mechanism of adjuvant action, including identifying the role of specific signaling pathways peptide based vaccines are going to become more attractive and more effective segment of therapeutics.

Although, the opinions of experts in this field are mixed, it is likely that with new product approvals and advanced research, the field of active peptide immunotherapy is self-assured for dramatic growth in the coming years. Using the gained knowledge and history of passive immunotherapy development as guiding tool, the peptides will revolutionize the market with modern treatment of varied diseases by the means of peptides vaccines.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers


  • $ 2500
  • February 2020

KEY FINDINGSThe global varicella live vaccine market is estimated to grow and record a CAGR of 5.78% during the forecast period of 2020-2028. The factors fueling the market growth are the rise in the awareness ...

Cholera - Pipeline Review, H1 2020

Cholera - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Cholera - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H1 2020, provides an overview of the Cholera (Infectious Disease) pipeline ...

Plague - Pipeline Review, H1 2020

Plague - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Plague - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H1 2020, provides an overview of the Plague (Infectious Disease) pipeline ...

Anthrax - Pipeline Review, H2 2019 $ 2000 November 2019


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on